Corbus Pharmaceuticals Holdings Inc
CRBP
NASDAQ
Biotechnology
$10.09
USD
+0.01 (+0.10%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $196.89M
Volume 425.8K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-101.90M
TTM
-75.8%
YoY
Operating Cash Flow
$-86.67M
TTM
-49.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 4.0 | 3.6 | 3.6 | 4.5 | 5.0 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 19.2 | 24.4 | 22.0 | 24.3 | 36.2 |
Operating Income | -19.2 | -24.4 | -22.0 | -24.3 | -36.2 |
EBITDA | -19.1 | -24.4 | -21.9 | -24.3 | -36.1 |
Other Income / Expense | 0.2 | -0.1 | 0.0 | -0.1 | -0.0 |
Total Other Income / Expense | 1.5 | 1.1 | 1.4 | 1.3 | 1.2 |
Income Before Income Taxes | -17.7 | -23.3 | -20.6 | -23.0 | -35.0 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -17.7 | -23.3 | -20.6 | -23.0 | -35.0 |
Consolidated Net Income / Loss | -17.7 | -23.3 | -20.6 | -23.0 | -35.0 |
Net Income Attributable to Common Shareholders | -17.7 | -23.3 | -20.6 | -23.0 | -35.0 |
Basic EPS | -$1.44 | -$1.90 | -$1.24 | -$1.23 | -$1.81 |
Diluted EPS | -$1.44 | -$1.90 | -$1.24 | -$1.23 | -$1.81 |
Basic Shares Outstanding | 12.2M | 12.3M | 16.5M | 18.7M | 19.4M |
Diluted Shares Outstanding | 12.2M | 12.3M | 16.5M | 18.7M | 19.4M |